Aurora kinase inhibitors--rising stars in cancer therapeutics? - Wikidata - wikimedia - TriplyDB

Aurora kinase inhibitors--rising stars in cancer therapeutics?

Aurora kinase inhibitors--rising stars in cancer therapeutics?

http://www.wikidata.org/entity/Q33647643

about

Identification of Ski as a target for Aurora A kinase Muscle-invasive urothelial bladder cancer: an update on systemic therapy Current and future trials of targeted therapies in cutaneous melanoma Development of o -Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis PIM1 kinase as a target for cancer therapy Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells Targeting kinase signaling pathways with constrained peptide scaffolds.Aurora kinase inhibition induces PUMA via NF-κB to kill colon cancer cells.StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors.MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA/B.Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models.Mitotic spindle proteomics in Chinese hamster ovary cells A new aurora in anaplastic thyroid cancer therapy.Functional kinomics identifies candidate therapeutic targets in head and neck cancer Targeting aurora kinase A inhibits hypoxia-mediated neuroblastoma cell tumorigenesis Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function The nuclear envelope environment and its cancer connections.Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer.PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains Management of diffuse pontine gliomas in children: recent developments.Kalanchoe tubiflora extract inhibits cell proliferation by affecting the mitotic apparatus Chromosomal instability in BRAF mutant, microsatellite stable colorectal cancers.Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice Tripolin A, a novel small-molecule inhibitor of aurora A kinase, reveals new regulation of HURP's distribution on microtubules.A network module-based method for identifying cancer prognostic signatures TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.Identification of potential synthetic lethal genes to p53 using a computational biology approach The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells.Advances in small-molecule drug discovery for triple-negative breast cancer.Synthesis of (E)-oxindolylidene acetate using tandem palladium-catalyzed Heck and alkoxycarbonylation reactions.

P2860

Q24304083-8B41B322-43C0-44AA-A05C-A4F7C05D1D06 Q26775780-A2FE0CD3-511C-4E93-9315-90DF6053D0A9 Q27022355-56ED9600-7F26-4FE7-910B-C8E731CB849C Q27670770-4357C037-CAD6-457B-B49A-3F85668D2A85 Q27851718-08F7A6A4-AB30-4D3D-B108-A0229E08CED8 Q27853047-58A13A34-4C77-45FC-BFEE-C7E95947F2B0 Q28261162-F47A5231-F1E2-40D0-8EDD-C28DA1B4370B Q28386389-07DF5394-32A8-405D-8CD1-ACEF6998B6B4 Q28545195-C0A56311-6295-4273-A95C-C28DA95DCC6E Q30398451-F296D603-D7B7-4C38-A941-C14A908EEED3 Q33579079-A10255AC-670A-457B-A455-823DD59EAB28 Q33679597-2912706A-2F7B-4CAE-A893-1A126D1C6598 Q33762222-97D0BBCA-10DA-4D81-B1F1-C771A95A932E Q33781657-BB8F4C95-DE19-4805-B151-5DD9E49E72BF Q33864179-A807C51A-5EFE-4786-9718-C4ACB118084B Q33915660-3AB8DD9D-C7E0-4F20-96BC-5DD94682A388 Q33925265-476C9958-6B4B-4966-BF93-87A2249E0319 Q33930368-0E2980B7-2A88-4141-BD55-2E8EB5CE4EB5 Q34055936-0F8BBBA1-B813-4314-8D1F-5DFB815FBE10 Q34194552-F67407A5-0462-4C8A-9E11-7A162D3DB9E2 Q34224775-53175E47-C01D-4D20-8C5A-773852B4824B Q34254678-609492C7-C14F-4F45-9CF7-2244CF033FB1 Q34281881-51AA2AD8-3B0E-4C82-98B1-F05AE738D227 Q34317305-611AFB71-3A04-4A89-8613-28ADE201F5E6 Q34338531-235F1581-A8BA-43E1-B962-F1FBFEBF6C20 Q34347540-121335D7-DDA5-4583-BDAD-8E704505D540 Q34410216-C0FEA3F1-D9D1-45B2-85F2-FB311126D582 Q34460444-3B373E7C-B8EA-452A-B059-5AAD3765CBA8 Q34544275-B9F8533F-2619-4F1A-9446-C7C554AC4623 Q34629643-4537EDCE-EDC6-4BBE-B27C-5D439B19B535 Q34646243-CCF1A228-DA2F-41EB-93F1-29E4FEC8225B Q34735167-51F93F02-2FF2-484F-A000-DD12DEFBD4B1 Q34982418-5167E3D3-12EC-4824-9DB5-F53D8DD1C56A Q34985284-2637ADCF-6FC2-48D2-932B-E5ECB8912589 Q35194626-A1B41AF0-AC1B-4F7F-85E8-D7444865948D Q35493637-EC0DBFEE-A957-4A65-B26B-197FF636F810 Q35558610-EB978213-66C4-4095-A13C-89E43532780C Q35666453-0C79CF43-E782-4D0C-8F58-559CD79B6767 Q35818491-2E2B6EC0-2289-4650-B4E1-586F8F02C2A9 Q35836288-7A8836BC-2B8E-4FF5-A898-B1BE682971D8

P2860

Aurora kinase inhibitors--rising stars in cancer therapeutics?

http://www.wikidata.org/entity/Q33647643

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Aurora kinase inhibitors--rising stars in cancer therapeutics?

@ast

Aurora kinase inhibitors--rising stars in cancer therapeutics?

@en

type

label

Aurora kinase inhibitors--rising stars in cancer therapeutics?

@ast

Aurora kinase inhibitors--rising stars in cancer therapeutics?

@en

prefLabel

Aurora kinase inhibitors--rising stars in cancer therapeutics?

@ast

Aurora kinase inhibitors--rising stars in cancer therapeutics?

@en

P1433

Q33647643-05AECC67-42BC-40AF-BEFB-C98AEF207B4E

P1476

Q33647643-4424DA27-832A-44B2-A872-6FACC2556945

P2093

Q33647643-4A311742-6429-4B04-A185-44013E748042

Q33647643-79A5F614-1999-4DA5-A0A5-CF26E987059C

Q33647643-896AB960-5EAA-4D16-9613-0037B4AE9D77

Q33647643-C328DCBD-8FA0-4D3D-BCA7-DB459F371EFE

Q33647643-F82BC6B9-D74D-4395-95EF-565AA11019E4

P2860

Q33647643-008CA54E-09FF-4EF0-BBE7-E3082C1B8FD3

Q33647643-0825EF07-E09E-4B1C-9F1D-533C8CD92EF3

Q33647643-094D42C2-F921-4D95-AD2B-F5FCB66DCA0B

Q33647643-0B98DB62-B81D-4791-A939-3953972632A6

Q33647643-0E067C7B-E9D1-4473-BB8B-AA79CA3EF54C

Q33647643-0E93362A-7BAA-475E-922C-AC39A0448DD7

Q33647643-152EA2B7-4FED-469B-8CC6-E563846F269F

Q33647643-1890DE04-10F6-4454-8819-2944509DA1A5

Q33647643-18EE131A-FBBF-42F9-AD8D-FBBB494BC9BA

Q33647643-1F4650D7-AED5-46A0-84BC-6368EBA8A7E7

P304

Q33647643-A8E01ED1-C033-4E4A-A3D1-CE7DC33310D3

P31

Q33647643-CAF4FE3E-5901-44B4-A732-9967CE9BC9DD

P356

Q33647643-40285E42-AB68-43EF-8548-E1E05A1E7968

P433

Q33647643-BA51BD39-1425-47BD-AF02-E47E474109F4

P478

Q33647643-88734B2B-79B1-475A-8F8D-CC81F3994906

P577

Q33647643-A936965D-558B-4766-BEFD-A86CF0CC83DF

P698

Q33647643-17701FD6-776C-40D3-B74C-4DDD3A6A7262

P932

Q33647643-48542041-8B12-4235-846C-DD6EE3F8E4AE

P356

1535-7163.MCT-09-0765

P1433

Molecular Cancer Therapeutics

P1476

Aurora kinase inhibitors--rising stars in cancer therapeutics?

@en

P2093

Altaf A Dar

http://www.w3.org/2001/XMLSchema#string

Jordan Berlin

http://www.w3.org/2001/XMLSchema#string

Laura W Goff

http://www.w3.org/2001/XMLSchema#string

Shahana Majid

http://www.w3.org/2001/XMLSchema#string

Wael El-Rifai

http://www.w3.org/2001/XMLSchema#string

P2860

Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells

Cdc20 associates with the kinase aurora2/Aik

The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

The mitotic regulator Survivin binds as a monomer to its functional interactor Borealin

Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3

Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells

Chromosomal passengers and the (aurora) ABCs of mitosis

Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells

P304

268-278

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-09-0765

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20124450

http://www.w3.org/2001/XMLSchema#string

P932

2820587

http://www.w3.org/2001/XMLSchema#string